Molecular heterogeneity of multiple myeloma: Pathogenesis, prognosis, and therapeutic implications

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1893-1897

  Avet Loiseau, Hervé ^a,b,c,d,e,f   Magrangeas, Florence ^a,b,c,d,e,f   Moreau, Philippe ^a,b,c,d,e,f   Attal, Michel ^a,b,c,d,e,f   Facon, Thierry ^a,b,c,d,e,f   Anderson, Kenneth ^a,b,c,d,e,f   Harousseau, Jean Luc ^a,b,c,d,e,f   Munshi, Nikhil ^a,b,c,d,e,f   Minvielle, Stéphane ^a,b,c,d,e,f  

^a University Hospital   (France)

^b INRA Institut National de la Recherche Agronomique   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB;

CARCINOGENESIS; CHROMOSOME 14Q; CHROMOSOME 17; CHROMOSOME TRANSLOCATION 14; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

CHROMOSOME DELETION; GENE DOSAGE; HUMANS; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 79955843637     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8435     Document Type: Review

References (54)

1. Dewald GW, Kyle RA, Hicks GA, et al: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-390, 1985 (Pubitemid 15007030)
2. Sawyer JR, Waldron JA, Jagannath S, et al: Cytogenetic finding in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41-49, 1995
3. Laï JL, Zandecki M, Mary JY, et al: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497, 1995
4. Calasanz MJ, Cigudosa JC, Odero MD, et al: Cytogenetic analysis of 280 patients with muliple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosom Cancer 18:84-93, 1997 (Pubitemid 27068906)
5. Smadja NV, Bastard C, Brigaudeau C, et al: Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2238, 2001
6. Debes-Marun C, Dewald G, Bryant S, et al: Chromosomal abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17:427-436, 2003 (Pubitemid 36266921)
7. Chng WJ, Kumar S, Vanwier S, et al: Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 67:2982-2989, 2007 (Pubitemid 46724834)
8. Nishida K, Tamura A, Nakazawa N, et al: The Ig heavy chain is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526-534, 1997 (Pubitemid 27299091)
9. Avet-Loiseau H, Li JY, Facon T, et al: High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58:5640-5645, 1998 (Pubitemid 29006396)
10. Fonseca R, Debes-Marun CS, Picken EB, et al: The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562-2567, 2003 (Pubitemid 37193596)
11. Chesi M, Bergsagel PL, Brents LA, et al: Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674-681, 1996 (Pubitemid 26240399)
12. Fonseca R, Blood EA, Oken MM, et al: Myeloma and the t(11;14)(q13;q32): Evidence for a biologically defined unique subset of patients. Blood 99:3735-3741, 2002 (Pubitemid 34534545)
13. Chesi M, Nardini E, Brents LA, et al: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264, 1997 (Pubitemid 27280209)
14. Chesi M, Nardini E, Lim RS, et al: The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025-3034, 1998 (Pubitemid 28492306)
15. Li Z, Zhu YX, Plowright EE, et al: The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 97:2413-2419, 2001 (Pubitemid 32291488)
16. Santra M, Zhan F, Tian E, et al: A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101:2374-2376, 2003 (Pubitemid 36302083)
17. Chesi M, Bergsagel PL, Shonukan OO, et al: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463, 1998 (Pubitemid 28270291)
18. Hurt EM, Wiestner A, Rosenwald A, et al: Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199, 2004 (Pubitemid 38283804)
19. Hanamura I, Iida S, Akano Y, et al: Ectopic expression of MAFB gene in human myeloma cells carrying the t(14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res 92:638-644, 2001 (Pubitemid 32633466)
20. Bergsagel PL, Kuehl WM, Zhan F, et al: Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 106:296-303, 2005 (Pubitemid 40967205)
21. Kuehl WM, Bergsagel PL: Multiple myeloma: Evolving genetic events and host interactions. Nature Rev Cancer 2:175-187, 2002 (Pubitemid 37328787)
22. Agnelli L, Bicciato S, Fabris S, et al: Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 92:56-65, 2007 (Pubitemid 46232658)
23. Hanamura I, Stewart JP, Huang Y, et al: Frequent gain of chromosome band 1q21 in plasma-cell hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732, 2006 (Pubitemid 44316143)
24. Drach J, Ackermann J, Fritz E, et al: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92:802-809, 1998 (Pubitemid 28355463)
25. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757, 2002 (Pubitemid 34533050)
26. Magrangeas F, Nasser V, Avet-Loiseau H, et al: Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101:4998-5006, 2003 (Pubitemid 36857764)
27. Zhan F, Huang Y, Colla S, et al: The molecular classification of multiple myeloma. Blood 108:2020-2028, 2006 (Pubitemid 44395016)
28. Broyl A, Hose D, Lokhorst H, et al: Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116:2543-2553, 2010
29. Annunziata CM, Davis RE, Demchenko Y, et al: Frequent engagement of the classical and alternative NFκB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115-130, 2007 (Pubitemid 47199123)
30. Keats JJ, Fonseca R, Chesi M, et al: Promiscuous mutations activate the noncanonical NFκB pathway in multiple myeloma. Cancer Cell 12:131-144, 2007 (Pubitemid 47208626)
31. Avet-Loiseau H, Li C, Magrangeas F, et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585-4590, 2009
32. Carrasco DR, Tonon G, Huang Y, et al: High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313-325, 2006
33. Shammas MA, Shmookler Reis RJ, Koley H, et al: Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 113:2290-2297, 2009
34. Zojer N, Königsberg R, Ackermann J, et al: Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925-1930, 2000
35. Desikan R, Barlogie B, Sawyer J, et al: Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010, 2000 (Pubitemid 30412882)
36. Facon T, Avet-Loiseau H, Guillerm G, et al: Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566-1571, 2001 (Pubitemid 32217218)
37. Fonseca R, Harrington D, Oken MM, et al: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 62:715-720, 2002 (Pubitemid 34126946)
38. Avet-Loiseau H, Attal M, Moreau P, et al: Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome. Blood 109:3489-3495, 2007 (Pubitemid 46572539)
39. Chang H, Sloan S, Li D, et al: The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125:64-68, 2004 (Pubitemid 38453279)
40. Gutiérrez NC, Castellanos MV, Martín ML, et al: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21:143-150, 2007 (Pubitemid 44921845)
41. Gertz MA, Lacy MQ, Dispenzieri A, et al: Clinical implications of t(11;14)(q13;q32), t(4;14) (p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106:2837-2840, 2005 (Pubitemid 41510761)
42. Moreau P, Attal M, Garban F, et al: Heterogeneity of t(4;14) in multiple myeloma: Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 21:2020-2024, 2007 (Pubitemid 47299977)
43. Fonseca R, Blood E, Rue M, et al: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575, 2003 (Pubitemid 36857829)
44. Nair B, van Rhee F, Shaughnessy JD Jr, et al: Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 115:4168-4173, 2010
45. Avet-Loiseau H, Malard F, Campion L, et al: Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor? Blood 117:2009-2011, 2011
46. Chang H, Qi C, Yi QL, et al: p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105:358-360, 2005 (Pubitemid 40053104)
47. Lodé L, Eveillard M, Trichet V, et al: Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95:1973-1976, 2010
48. Fonseca R, Van Wier SA, Chng WJ, et al: Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20:2034-2040, 2006 (Pubitemid 44614894)
49. Decaux O, Lodé L, Magrangeas F, et al: Prediction of survival in multiple myeloma based on gene-expression profiles revealed cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myélome. J Clin Oncol 26:4798-4805, 2008
50. Shaughnessy JD, Zhan F, Burrington BE, et al: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276-2284, 2007 (Pubitemid 46425864)
51. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
52. Pineda-Roman M, Zangari M, Haessler J, et al: Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol 140:625-634, 2008 (Pubitemid 351300910)
53. Avet-Loiseau H, Leleu X, Roussel M, et al: Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630-4634, 2010
54. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed myeloma. Blood 116:679-686, 2010